Summary of the interim report
Fourth quarter of 2023
Remaining business operations
- Net sales 0.0 MSEK (2.2 MSEK)
- Other income 0.2 MSEK (0.2 MSEK)
- R&D costs for the quarter amounted to 1.5 MSEK (8.6 MSEK)
- Profit after tax amounted to -7.9 MSEK (-12.9 MSEK)
- Earnings per share for the quarter amounted to
- Cash flow from operating activities amounted to -13.3 MSEK (-10.7 MSEK)
Business operations for sale
- Profit after tax amounted to -1.6 MSEK
The period January-
Remaining business operations
- Net sales 0.0 MSEK (5.9 MSEK)
- Other income 0.2 MSEK (0.7 MSEK)
- R&D costs for the period amounted to 4.5 MSEK (51.4 MSEK)
- Profit after tax amounted to -18.4 MSEK (-63.8 MSEK)
- Earnings per share for the period amounted to
- Cash flow from operating activities amounted to -15.4 MSEK (-49.8 MSEK)
Business operations for sale
- Profit after tax amounted to -17.4 MSEK
- Earnings per share for the quarter amounted to
For more information, visit the
investor.relations@klaria.com
Tel: +46 (0) 8-446 42 99
This is
Klaria (
https://news.cision.com/klaria-pharma-holding-ab/r/klaria-year-end-report-2023,c3938520
https://mb.cision.com/Main/12655/3938520/2639095.pdf
https://mb.cision.com/Public/12655/3938520/9215574785d2dc03.pdf
(c) 2024 Cision. All rights reserved., source